4502 (4502) News
Follow 4502 (4502) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial
TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis.Zasocitinib i
NEWS | Sep 30, 2026, 06:19 AM UTC
L
Takeda Pharmaceutical Company Limited Reports Phase 3 Superiority of Zasocitinib vs Deucravacitinib
Takeda reported Phase 3 head-to-head data showing zasocitinib achieved statistical superiority over deucravacitinib across primary and key secondary endpoints in moderate-to-severe plaque psoriasis, with higher complete
NEWS | Sep 30, 2026, 05:00 AM UTC
L
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibit
NEWS | Sep 30, 2026, 05:00 AM UTC
L
Pharma sector doubles down on AI to slash costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency across their pipelines.Industry
NEWS | Sep 29, 2026, 01:35 PM UTC
L
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) NASDAQ:KROS, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide
NEWS | Sep 29, 2026, 12:09 PM UTC
L
FDA Directs Takeda To Add Boxed Warning To Adzynma Drug Label
FDA
REGULATION | Sep 23, 2026, 10:13 PM UTC
L
Roche proposes former Takeda CEO for board seat
Roche BX:RHO on Wednesday said it was proposing Christoph Weber, the former CEO of Takeda Pharmaceuticals TSE:4502, for election to the Swiss company's board of directors at its AGM next March."Christophe's intimate know
NEWS | Sep 23, 2026, 05:09 AM UTC
M
Takeda Qdenga dengue vaccine to be distributed in India by Dr Reddy’s in 2027
Takeda said it will bring Qdenga to India via an exclusive distribution agreement with Dr Reddy’s, expected in the first half of 2027.
EQUITY | Sep 18, 2026, 05:42 AM UTC
M
Dr Reddy’s signs deal to promote and distribute Takeda’s Qdenga in India
Dr Reddy's Laboratories said it signed an agreement with Takeda Pharmaceutical to promote and distribute Qdenga in India, months after India’s regulator approved Qdenga for use in both children and adults.
MNA | Sep 18, 2026, 03:53 AM UTC
L
Weekly Recap: Mimrylo approved for Polycythemia Vera and zasocitinib NDA
Takeda Pharmaceutical Co. Ltd. Sponsored ADR (TSE:4502) scored an FDA win with Mimrylo (rusfertide) approval for polycythemia vera after Phase 3 VERIFY showed superior hematocrit control and fewer phlebotomies, while the
REGULATION | Sep 14, 2026, 10:15 PM UTC
L
Takeda Pharmaceutical Company: Upcoming launches and data readouts signal a major inflection point for growth and innovation
Leadership transition is underway with a new CEO set to unveil strategy at December's Capital Markets Day. Key launches include ORZEYFUL for narcolepsy and zasocitinib for psoriasis and IBD, with robust clinical data and
NEWS | Sep 14, 2026, 08:07 PM UTC
L
Takeda Pharmaceutical Company: Major launches and data readouts drive a pivotal strategic shift, with new leadership at the helm
Leadership transition is underway with a new CEO set to unveil strategy at December’s Capital Markets Day. Key launches include ORZEYFUL for narcolepsy and zasocitinib for immunology, both with competitive pricing and ro
NEWS | Sep 14, 2026, 07:38 PM UTC
L
Takeda to retire R&D president Andy Plump effective June 2027
Takeda Pharmaceutical Company Limited announced planned retirement of its President of Research & Development, Andy Plump, effective June 2027.
EQUITY | Sep 10, 2026, 09:34 AM UTC
M
NEJM publishes Phase 3 data for oveporexton in narcolepsy type 1
Takeda said the New England Journal of Medicine published results from two Phase 3 studies of oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).
EQUITY | Sep 09, 2026, 12:24 PM UTC
L
Weekly Recap: MIMRYLO license terms and Orzeyful FDA approval
Weekly Recap: MIMRYLO license terms and Orzeyful FDA approval
REGULATION | Aug 31, 2026, 10:14 PM UTC
L
Trump administration to announce drug pricing deals
TradingView News reports the Trump administration will announce drug pricing deals.
EQUITY | Aug 31, 2026, 04:07 PM UTC
M
FDA approves Takeda’s Mimrylo for polycythemia vera
FDA has approved Takeda’s Mimrylo for the rare blood disorder polycythemia vera.
REGULATION | Aug 29, 2026, 04:03 AM UTC
M
FDA approves Takeda’s Mimrylo for blood cancer
Takeda’s Mimrylo received FDA approval to treat a blood cancer condition.
REGULATION | Aug 28, 2026, 11:02 PM UTC
M
US FDA approves Takeda and Protagonist rare blood cancer drug
US FDA approved Takeda and Protagonist's drug for a rare blood cancer.
REGULATION | Aug 28, 2026, 09:37 PM UTC
L
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In September 2026
REGULATION | Aug 26, 2026, 03:27 PM UTC